1. Introduction {#sec0001}
===============

More than a third of a century has elapsed since the first MRI studies of white matter lesions in multiple sclerosis (MS) patients ([@bib0031]; [@bib0068]), paving the path for the current role of MRI as a staple for MS diagnosis and monitoring ([@bib0015]; [@bib0062]). Routine clinical practice is dominated by conventional MRI sequences such as T2-weighted imaging with fluid attenuated inversion recovery (FLAIR) and contrast-enhanced T1-weighted scans, which provide important, albeit limited information on subclinical disease activity and effectiveness of treatment. Notably, the derived measures such as T2 lesion load do not strongly correlate with the clinical findings of MS patients ([@bib0003]) and neglect some aspects of central nervous system damage visible at the histological level, calling for more sensitive MRI markers of microstructural injury accumulation and disease progression, even more so with the advent of new disease modifying therapies (DMT) ([@bib0059]).

Substantial research efforts have been invested into the detection of alterations in grey matter (GM) ([@bib0006]; [@bib0007]; [@bib0011]; [@bib0020]; [@bib0050]), impending plaques in the normal appearing white matter (NAWM) ([@bib0014]; [@bib0058]; [@bib0063]; [@bib0064]; [@bib0065]), and the recognition of subtle microstructural changes in the NAWM itself ([@bib0005]; [@bib0017]; [@bib0041]). Myelin reduction, axonal pathology and diffuse microglial activation in NAWM ([@bib0041]) are thought not only to contribute to the clinical picture, but to reflect the very nature of MS as a global inflammatory response in the whole brain originally stemming from a few focal flares of demyelination ([@bib0025]). One way of addressing these issues is offered by quantitative MRI techniques, including magnetization transfer (MT) ([@bib0048]) and diffusion tensor imaging (DTI) ([@bib0008]). Although not commonly used in clinical practice, magnetization transfer ratio has been proven to correlate inversely with myelin loss, axonal damage ([@bib0052]) and disease severity measures ([@bib0060]). Also, macromolecular proton fraction mapping provides direct measure of demyelination in the brain ([@bib0066]; [@bib0067]). Diffusion tensor imaging (DTI) indices such as mean diffusivity (MD), fractional anisotropy (FA), axial diffusivity (AD) and radial diffusivity (RD) are sensitive to tissue integrity, axonal damage and myelin loss ([@bib0042]), and the reduced T2\* relaxation time is thought to be associated with GM iron deposition as a sign of neurodegeneration in MS patients ([@bib0026]). Moreover, the ratio of T1-weighted and T2-weighted images (T1w/T2w ratio) has recently emerged as a viable candidate for the assessment of white matter (WM) injury in MS ([@bib0005]). Unfortunately, the reported differences in T1w/T2w ratio between healthy individuals and MS patients are subtle and require large sample sizes, impeding adoption of these techniques in clinical practice.

The emerging pharmacological methods specifically targeting selected pathways of MS pathology, such as drugs aimed at augmenting remyelination or preventing neurodegeneration, necessitate new approaches for monitoring microstructural disease activity ([@bib0062]). Several lines of theoretical and experimental evidence indicate that rotating frame quantitative MRI mapping techniques which utilize frequency swept pulses are valuable tools for tissue characterization in MS ([@bib0032]) and other diseases ([@bib0034]; [@bib0037]; [@bib0054]; [@bib0043]; [@bib0029]). Whereas free-precession T1 and T2 relaxations due to dipolar interactions depend on magnetic field fluctuations at frequencies near the Larmor frequency in the MHz range, the rotating frame relaxations detect additional information from lower frequencies in the kHz range of the effective fields generated by the radio-frequency pulse. This inherent sensitivity of adiabatic T1ρ ([@bib0039]), T2ρ ([@bib0038]) and non-adiabatic RAFF (Relaxation Along a Fictitious Field) ([@bib0030]) to slower motional regimes provides the ability to capture the large spectrum of water dynamics closely associated with the fine microstructure of various tissues. Indeed, the highly compartmentalized nature of WM consisting of axons, myelin sheaths and inter-axonal space, and the very character of MS disrupting myelin as the main barrier to inter-compartmental water exchange, demand acquisition protocols focused on slow motional regimes, as the mean residence time of myelin water protons varies in the range of hundreds of milliseconds to microsecond time scale ([@bib0012]). Ergo, of particular relevance in this context is RAFFn (n standing for the rank of the rotating frame) due to the possibility of "fine-tuning" the contrast to different motional regimes and therefore tissue characteristics, as evidenced by the recent confirmation of RAFF4 and RAFF5 as a highly sensitive marker of myelin content ([@bib0022]; [@bib0051]).

The overall goal of this cross-sectional study was to detect subtle abnormalities of multiple tissue types in patients with relapsing-remitting MS, including the whole WM, NAWM, diffusely abnormal WM (DAWM), cortical GM and subcortical GM. Towards this aim, we utilized imaging protocols of rotating frame MRI on a clinical 3 Tesla platform, in combination with DTI and conventional T1- and T2-weighted images as additional markers of microstructural damage, and resting-state functional MRI (rsfMRI) as a marker of functional impairment of relevant regions of interest. Based on our previous pilot study in MS patients ([@bib0032], 1), we hypothesised that both RAFF4 and T1ρ are able to detect significant differences between MS patients and controls, specifically in NAWM, superior to the capabilities of DTI and conventional protocols, including their derivatives as T1w/T2w ratio.

2. Methods {#sec0002}
==========

2.1. Subjects {#sec0003}
-------------

Ten patients with relapsing-remitting MS diagnosed in accordance with the 2010 revised McDonald Criteria ([@bib0044]) were recruited from the University of Minnesota MS Clinic between June 2015 and April 2016. Demographic (sex, age) and basic neurologic data including disease history were obtained on the day of the MRI acquisition at the Center for Magnetic Resonance Research, complemented with the following quantitative measures: Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), Fatigue Severity Scale (FSS), Symbol Digit Modalities Test (SDMT), center for Epidemiologic Studies Depression Scale (CES-D), and the Multiple Sclerosis Quality of Life-54 instrument (MSQOL). Additionally, we recruited ten frequency sex- and age-matched healthy controls. We did not include patients with a history of recent MS relapse or MS therapy change (within 6 months of enrollment), individuals with MRI contraindications, comorbid psychiatric or neurological disorder other than MS, or evidence of significant vascular or space occupying lesions in MRI scans.

This study was carried out in accordance with the recommendations of The Code of Federal Regulations. The protocol was approved by the Institutional Review Board: Human Subjects Committee of the University of Minnesota. A written informed consent was provided by each subject in accordance with the Declaration of Helsinki.

2.2. Imaging protocol {#sec0004}
---------------------

The MRI acquisition was performed using a 3 Tesla Siemens Prisma system. T1-weighted, T2-weighted images and DTI covered the whole brain. Magnetization-prepared rapid gradient-echo (MPRAGE) sequence was used for T1-weighted acquisitions, with the repetition time (TR) of 2150 ms, time to echo (TE) of 2.47 ms, inversion time (TI) of 1100 ms, voxel size of 1 × 1 × 1 mm^3^, flip angle of 8° and generalized autocalibrating partial parallel acquisition (GRAPPA) = 2. T2-weighted images were collected using the SPACE sequence, voxel size = 1 × 1 × 1 mm^3^, TE = 147 ms and GRAPPA = 2. Manufacturer-implemented pre-scan normalized algorithm was employed in both T1-weighted and T2-weighted scans. DTI datasets were acquired utilizing the following parameters: TR = 2820 ms, TE = 72.6 ms, multi band (MB) = 4, in 128 directions, with 5 additional non-diffusion weighted (b0) images, b-value = 1500 s/mm^2^, voxel size = 1.8 × 1.8 × 1.8 mm^3^. The acquisitions were repeated with opposite phase encoding along the antero-posterior and postero-anterior axis. rsfMRI data was obtained using gradient echo Echo Planar Imaging (EPI) sequence, with TR = 900 ms, TE = 30 ms, and multi band factor = 4. Voxel size of 3 × 3 × 3 mm^3^ and matrix size of 64 × 64, 48 slices with interleaved slice acquisition was used to acquire 502 volumes in total. Rotating frame relaxation measurements including adiabatic T1ρ, T2ρ and RAFF4 were obtained from 30 slices aligned to the anterior and posterior commissure and covering the whole supratentorial area and a part of the brainstem and cerebellum (voxel size = 1.6 × 1.6 × 3.6 mm^3^, GRAPPA = 3, TE = 3.18 ms and TR = 2 s). The rotating frame MRI protocols have been described previously ([@bib0034]). Briefly, hyperbolic secant pulses ([@bib0055]; [@bib0016]) with adiabaticity factor *R* = 10, pulse duration = 6 ms, bandwidth BW = 1.3 kHz, peak power ω~1~^max^/(2π) = 800 Hz, and number of pulses = 0, 4, 8, 12, 16 MLEV phase cycled ([@bib0027]) were used for adiabatic T1ρ and T2ρ measurements. For RAFF4 acquisitions, pulse duration was 4.56 ms, number of pulses = 0, 4, 8, 12, 16 and ω~1~^max^/(2π) = 327 Hz. Segmented gradient echo readout (2 segments) was used for imaging readout in all rotating frame relaxation measurements.

2.3. Image analysis {#sec0005}
-------------------

In the preliminary pre-processing step, manually defined masks of all T2-hyperintense WM lesions were used to reduce the intensity contrast within the WM lesion areas in T1w scans of MS subjects utilizing the previously published "lesion-filling" process ([@bib0004]). The aim of this procedure was to avoid incorrect automatic segmentation of juxtacortical MS lesions as GM in the subsequent analysis. Further analysis was performed using the human connectome project (HCP) minimal preprocessing pipeline ([@bib0018]), consisting of the PreFreesurfer, FreeSurfer (FreeSurfer 5.3-HCP; <http://surfer.nmr.mgh.harvard.edu/>) and PostFreesurfer step for the structural data. The accuracy of the segmentation in each subject was visually inspected by a trained operator (P.F.). The PostFreesurfer step and all subsequent relevant analyses utilized the T1-weighted scan without the preliminary lesion correction so that correct T1w/T2w ratios were obtained for lesion areas.

The following masks for regions of interest (ROIs) were derived from the automatic labelling results in each subject: whole WM, cortical GM, basal ganglia, thalamus, hippocampus and amygdala. Furthermore, the whole WM was carefully segmented into three distinct WM types (NAWM, DAWM and lesions) utilizing a hybrid, semi-automatic approach, where two specific T2 intensity thresholds (distinguishing NAWM / DAWM and DAWM / lesions) were individually selected for each MS patient based on thorough visual evaluation by two neurologists (A.C., an MS specialist, and P.F.) in the normalized T2-weighted scans coregistered to the T1-weighted scan (see [Fig. 1](#fig0001){ref-type="fig"}). For the purposes of this study, DAWM was considered WM with T2 intensity above the normal values expectable for healthy WM but still below intensities which were considered true lesions. This approach consistently identified DAWM in all MS patients. No further cluster thresholding or erosion of these masks were performed, as these steps introduced inconsistent results across individuals and did not improve a possible major concern of the interference of partial volume effects. Nonetheless, this concern was solved at a later step of processing during the coregistration of these masks to lower resolution images, where only coregistered voxels with an intensity of at least 0.9 after trilinear interpolation of the original binary WM masks were considered in further analyses (see the Supplementary figure 2 for visualisation). This value is generally recommended as a conservative threshold. The acquired MRI scans were not optimized for the detection of cortical GM lesions, so no corresponding GM segmentation was performed. T1w/T2w ratio as calculated in the HCP minimal preprocessing data was used in the subsequent analyses.Fig. 1Image slice from a representative MS subject: (A) native T2-weighted image depicting significant white matter (WM) abnormalities; (B) superimposed WM ROIs created by a semi-automated approach based on individual T2 intensity thresholds, including normal appearing WM (green), diffusely abnormal WM (brown) and lesions (red). Radiological laterality conventions (with the right side of the figure corresponding to the left side of the brain) are used.Fig. 1

A 2-step 3D rigid body motion correction was performed in T1ρ, T2ρ and RAFF4 scans utilizing the MCFLIRT algorithm implemented in FSL 5.0.6 ([@bib0024], [@bib0023]). All acquired scans were co-registered to the first acquisition of the relevant sequence utilizing the default MCFLIRT parameters (6 degrees of freedom, trilinear interpolation and normalized correlation as cost function). It is important to emphasize that the contrasts of individual scans with rising numbers of pulses are at the borderline between the requirements for within-modality and between-modality cost functions, i.e. similar, but not completely identical as presumed for normalized correlation. However, both visual inspection of the coregistered scans and motion inspection (root-mean-squared voxel displacement) showed that MCFLIRT yielded a satisfactory result (motion less than one voxel). Afterwards, the relaxation time constants of individual sequences were calculated using custom routines based on the Aedes software package (<http://aedes.uef.fi>) in MATLAB R2016a (MathWorks, Inc., Natick, MA). 2-parameter non-linear fitting was used to estimate M0 and relaxation time in T1ρ and T2ρ acquisitions, and a 4-parameter non-linear fitting for M0, Mss (steady state value of magnetization), Mz (initial magnetization value measured from the negative hemisphere) and relaxation time for RAFF4 acquisitions. In the following step, T1ρ, T2ρ and RAFF4 maps were co-registered (3D rigid body co-registration) to the anatomical scan using the BB-register algorithm as implemented in FreeSurfer 6.0 with mri_robust_register initialisation ([@bib0046]), to create co-registration matrices used in the subsequent steps for inverse co-registration of structural masks to these lower resolution images.

DWI datasets were processed utilizing the HCP minimal preprocessing pipeline ([@bib0018]), with subsequent diffusion tensor fitting to generate FA, MD, AD and RD ([@bib0002]; [@bib0001]). rsfMRI acquisitions were also analysed using the HCP minimal preprocessing pipeline followed by the HCP rsfMRI post-processing pipeline ([@bib0056]). HCP training data was used for the FIX auto-classification algorithm ([@bib0049]) with subsequent manual examination and amendments to the FIX-derived labelling of artefactual components before the regression of their contribution out of the rsfMRI data. The AFNI package ([@bib0010]) was utilized to calculate voxel-wise degree centrality (DeCe) and regional homogeneity (ReHo) based on the cleaned volumetric output of the pipeline.

Subsequently, the masks derived from automatic segmentation and semi-automatically created WM masks (NAWM, DAWM, and lesions) were co-registered to the images with lower resolution to avoid oversampling and the inherently associated obscurity. The inverse matrices created by 3D rigid body co-registration of T1ρ, T2ρ and RAFF maps to the T1-weighted scan were utilized and the resulting co-registrations of individual images and masks were visually inspected in every subject. Only voxels with a probability of inclusion in the relevant ROI of at least 0.9 were utilised in the subsequent image masking to avoid the "bleeding" of mixed information from adjacent voxels located at the interfaces of individual tissue types / ROIs.

2.4. Statistical analyses {#sec0006}
-------------------------

Equivalence analysis (two one-sided tests) was used to confirm the absence of statistically significant differences (type I error = 0.05) in sex and age between the MS patients and healthy controls, with the differences of 33% and 10 years for sex and age considered clinically relevant. Quantitative clinical data were summarized using descriptive statistical approaches.

Means of the MRI metrics (adiabatic T1ρ, and T2ρ, RAFF4, FA, MD, AD, RD and T1w/T2w ratio; and DeCe and ReHo for GM masks only) were calculated within the individual ROIs per subject. Normality of these mean values was assessed with the Kolmogorov--Smirnov test per ROI. T1ρ, T2ρ, RAFF4, T1w/T2w ratio, FA, MD, AD and RD per-subject histograms were created for the whole WM ROI, separately for MS patients and controls, and per-subject skewness and kurtosis were calculated for these histograms to provide additional information about eventual between-group shape differences. Note that we refer to histograms of relaxation times as relaxograms.

Comparisons of MRI parameters were carried out between healthy controls whole WM and MS patients for each of whole WM, NAWM, DAWM, and WM lesions and between healthy controls and MS patients for each of cortical GM, basal ganglia, thalamus, amygdala, and hippocampus; two-tailed two-sample t-tests were used. A type I error rate of 0.05 was used after false discovery rate (FDR) correction for multiple modalities (8: T1w/T2w ratio, T1ρ, T2ρ, RAFF4, MD, FA, DeCe, ReHo) and ROIs (9). Separate FDR correction with was implemented for two-tailed two-sample t-tests of kurtosis and skewness, incorporating 6 modalities (T1w/T2w ratio, T1ρ, T2ρ, RAFF4, MD, FA) and 2 measures (kurtosis and skewness). Note that AD and RD were not included among the primary modalities due to their redundancy with FA and MD metrics. Pearson\'s correlation analysis was carried out to correlate individual clinical measures of interest (7: disease duration, EDSS, MSFC, SDMT, FSS, CES-D, MSQoL) with mean MRI parameter per ROI (9 ROIs, with the exception of rsfMRI measures, where 5 ROIs were considered, and 8 MRI parameters) with similar FDR correction.

2 scatter plots of mean T1ρ vs. mean T2ρ relaxation times were added to further elucidate the results: (1) scatterplot in whole WM to show the clustering of healthy controls and MS patients; and (2) scatterplot in segmented WM to show the clustering of NAWM, DAWM and lesions in MS patients.

Lastly, the volumes of 7 ROIs (WM, cortical GM, lateral ventricles, basal ganglia, thalamus, amygdala, hippocampus) and the volume of the whole brain, as provided by the automatic segmentation algorithm of FreeSurfer, were compared between the MS patients and healthy subjects using two-sided two-sample t-tests.

3. Results {#sec0007}
==========

3.1. Demographics {#sec0008}
-----------------

The two one-sided tests confirmed the equivalence of both sex and age distributions between the two study groups (sex, *p* = 0.048; age, *p* = 0.030, for MS subjects and healthy controls, respectively). Demographic information is provided in [Table 1](#tbl0001){ref-type="table"}. The average disease duration of the MS group was 12.10 years (SD 4.82). Four MS patients reached EDSS stage 4 (gait impairment), the other six subjects ranged from 1 to 2 (without gait impairment). All MS subjects were on a stable DMT regimen: dimethyl fumarate -- 4 subjects; glatiramer acetate -- 2 subjects; natalizumab -- 2 subjects; fingolimod and teriflunomide -- 1 subject each. For further clinical information, see [Table 1](#tbl0001){ref-type="table"}.Table 1Demographics and clinical characteristics of all subjects. Scores provided as mean ± standard deviation (range). *EDSS* Expanded Disability Status Scale, *MSFC* Multiple Sclerosis Functional Composite, *FSS* Fatigue Severity Scale, *SDMT* Symbol Digit Modalities Test, *CES-D* centre for Epidemiologic Studies Depression Scale, *MSQoL* Multiple Sclerosis Quality of Life-54.Table 1Healthy controlsMS patients*N*1010*Gender (female/male)*8/28/2*Age \[years\]*46.0 ± 13.4 (20--62)47.3 ± 11.8 (19--59)*Disease duration \[years\]*--12.1 ± 4.8 (5--17)*EDSS*--2.7 ± 1.2 (1.0--4.0)*MSFC*--0.28 ± 0.49 (0.79--0.84)*SDMT*--52.9 ± 14.0 (35--83)*FSS*--39.6 ± 14.2 (17--60)*CES-D*--11.2 ± 9.4 (1--34)*MSQoL, physical section*--65.7 ± 18.0 (35.2--86.1)*MSQoL, mental section*--74.4 ± 15.7 (42.6--87.5)

3.2. ROI masks {#sec0009}
--------------

The mean thresholds for the individually created WM masks in MS patients based on T2-weighted signal intensities (see [Fig. 1](#fig0001){ref-type="fig"}, numbers in a.u.) were 228.0 (range of 175--266) and 264.4 (range of 196--310) for the NAWM/DAWM and DAWM/lesion cut-offs, respectively. This considerable inter-subject variability and overlap of the ranges at the group level (perceived even in T2-weighted images processed using the pre-scan normalization implemented by the MRI scanner manufacturer) precludes determining any simple numeric cut-off value plausible for all the MS subjects. All the created NAWM, DAWM, and lesion masks were manually inspected (A.C., an MS specialist, and P.F.), but no further local manual corrections were performed. Although this approach also labelled juxtacortical WM voxels with slightly increased intensities in some areas as DAWM, it was not possible to truly differentiate between partial volume effects due to insufficient resolution and juxtacortical lesions.

Kolmogorov--Smirnov tests confirmed the absence of significant deviations from the normal distribution (*p* \> 0.05) for the averages of voxel values for individual MRI sequences and all ROIs with sufficient number of voxels, enabling us to use parametric statistical methods. However, normality could not be confirmed for the lesional WM masks in lower resolution methods, so not only the paucity of values, but also the distribution of relevant values in these areas, call for caution in eventual interpretation of borderline results.

3.3. T1ρ focal abnormalities {#sec0010}
----------------------------

Visual inspection of the processed scans revealed multiple conspicuous T1ρ focal abnormalities in 4 MS patients (out of 10) (see [Fig. 2](#fig0002){ref-type="fig"}), while no healthy controls showed comparable findings. Interestingly, no other sequence, including the T2-weighted images, detected any corresponding lesions in these areas (mostly WM in the vicinity of the lateral ventricles, namely several parts of the corpus callosum, but also caudate and thalamus). Notably, while T2-hyperintense lesions displayed prolonged relaxation time constants in T1ρ maps, the T1ρ relaxation time constants in these focal abnormities were substantially shorter. As the true nature of these T1ρ focal abnormalities is unclear as of now, no further changes in the T2w-based NAWM masks were performed to exclude these regions. Nonetheless, due to the scarcity of these abnormalities, even excluding these areas from NAWM masks resulted in negligible numerical differences in the averages and standard deviations beyond the precision of values provided in the [Table 2](#tbl0002){ref-type="table"}.Fig. 2T1-weighted (left), T2-weighted (middle) and T1ρ (right) images with reconstructed surfaces for better orientation of 4 MS subjects with conspicuous T1- and T2-negative T1ρ lesions in the periventricular white matter (A and B), in the bilateral thalami (C) and in the genu of corpus callosum (D). The MS subject in (D) had also a similar lesion in the head of the right caudate (not depicted). Black arrows point to the lesions of interest. The scales denote relaxation time in \[ms\]. Radiological laterality conventions (with the right side of the figure corresponding to the left side of the brain) are used. The dark regions in the cerebrospinal fluid in the T2-weighted images are probably caused by the inherent susceptibility of the T2-weighted scans to the loss of phase in highly heterogeneous substances and possibly flow changes, sometimes described as "flow void".Fig. 2Table 2MRI metrics in the regions of interest. *T*-test, false discovery rate corrected for multiple modalities (6 for white matter and 8 for grey matter) and ROIs (9). Statistically significant results (*p* \< 0.05, corrected) are marked in bold italics. For AD and RD, no FDR correction is provided, as these are only included for completeness and mirror their compound variable -- MD. Positive *T*-values denote higher values of respective parameters in MS patients. WM: white matter; NAWM: normal appearing WM; DWM: "dirty" WM.Table 2MRI metricRegion of InterestControls (mean ± SD, *n* = 10)MS patients (mean ± SD, *n* = 10)difference (patients minus controls)*T*-value*p*-value, uncorr*p*-value, FDR-corrRAFF4 \[ms\]Whole WM253 ± 7269 ± 96.4%4.630.0002***0.0011***NAWM253[\*](#tb2fn1){ref-type="table-fn"} ± 7[\*](#tb2fn1){ref-type="table-fn"}262 ± 73.5%2.880.0099***0.0317***DWM253[\*](#tb2fn1){ref-type="table-fn"} ± 7[\*](#tb2fn1){ref-type="table-fn"}266 ± 85.3%3.940.0010***0.0038***WM lesions253[\*](#tb2fn1){ref-type="table-fn"} ± 7[\*](#tb2fn1){ref-type="table-fn"}356 ± 4140.9%7.880.0000***0.0000***Thalamus272 ± 8278 ± 72.1%1.740.09870.1707Amygdala329 ± 12338 ± 72.6%1.910.07170.1391Hippocampus314 ± 10328 ± 74.5%3.620.0019***0.0069***Basal ganglia296 ± 8305 ± 103.0%2.160.04490.0991Cortex334 ± 9342 ± 82.3%2.060.05450.1163T1ρ \[ms\]Whole WM131 ± 5142 ± 48.1%5.590.0000***0.0002***NAWM131[\*](#tb2fn1){ref-type="table-fn"} ± 5[\*](#tb2fn1){ref-type="table-fn"}136 ± 23.3%2.640.0167***0.0485***DWM131[\*](#tb2fn1){ref-type="table-fn"} ± 5[\*](#tb2fn1){ref-type="table-fn"}146 ± 411.2%7.250.0000***0.0000***WM lesions131[\*](#tb2fn1){ref-type="table-fn"} ± 5[\*](#tb2fn1){ref-type="table-fn"}203 ± 2454.4%9.270.0000***0.0000***Thalamus146 ± 4149 ± 12.0%2.290.03410.0840Amygdala170 ± 5172 ± 41.2%1.030.31560.4489Hippocampus166 ± 3172 ± 74.0%2.730.0137***0.0417***Basal ganglia148 ± 3152 ± 42.5%2.360.02970.0761Cortex163 ± 3166 ± 41.6%1.850.08080.1520T2ρ \[ms\]Whole WM71 ± 275 ± 36.2%4.250.0005***0.0024***NAWM71[\*](#tb2fn1){ref-type="table-fn"} ± 2[\*](#tb2fn1){ref-type="table-fn"}71 ± 20.4%0.320.74900.8560DWM71[\*](#tb2fn1){ref-type="table-fn"} ± 2[\*](#tb2fn1){ref-type="table-fn"}80 ± 313.3%7.890.0000***0.0000***WM lesions71[\*](#tb2fn1){ref-type="table-fn"} ± 2[\*](#tb2fn1){ref-type="table-fn"}113 ± 1459.4%9.520.0000***0.0000***Thalamus72 ± 173 ± 21.6%1.550.13890.2279Amygdala88 ± 289 ± 21.6%1.990.06180.1236Hippocampus86 ± 289 ± 23.8%4.030.0008***0.0036***Basal ganglia66 ± 266 ± 31.0%0.600.55450.6824Cortex80 ± 281 ± 21.4%1.310.20740.3238T1w/T2w ratioWhole WM1.21 ± 0.061.13 ± 0.05−6.7%−3.120.0059***0.0197***NAWM1.21[\*](#tb2fn1){ref-type="table-fn"} ± 0.06[\*](#tb2fn1){ref-type="table-fn"}1.15 ± 0.05−5.1%−2.410.02710.0723DWM1.21[\*](#tb2fn1){ref-type="table-fn"} ± 0.06[\*](#tb2fn1){ref-type="table-fn"}0.86 ± 0.07−29.1%−11.950.0000***0.0000***WM lesions1.21[\*](#tb2fn1){ref-type="table-fn"} ± 0.06[\*](#tb2fn1){ref-type="table-fn"}0.61 ± 0.08−49.3%−17.870.0000***0.0000***Thalamus1.22 ± 0.041.20 ± 0.06−1.6%−0.830.41750.5463Amygdala0.80 ± 0.030.79 ± 0.02−2.3%−1.670.11280.1899Hippocampus0.81 ± 0.030.78 ± 0.03−3.6%−2.520.02160.0601Basal ganglia1.16 ± 0.051.14 ± 0.08−1.7%−0.650.52080.6535Cortex0.80 ± 0.030.78 ± 0.03−2.0%−1.140.27050.3935FAWhole WM0.50 ± 0.020.48 ± 0.02−4.2%−2.220.03960.0938NAWM0.50[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}0.48 ± 0.02−3.5%−2.040.05650.1167DWM0.50[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}0.43 ± 0.04−14.1%−4.780.0002***0.0009***WM lesions0.50[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}0.31 ± 0.05−38.3%−10.920.0000***0.0000***Thalamus0.34 ± 0.020.35 ± 0.033.9%1.320.20430.3238Amygdala0.17 ± 0.010.18 ± 0.025.3%1.180.25480.3792Hippocampus0.14 ± 0.020.13 ± 0.01−7.2%−1.810.08770.1600Basal ganglia0.18 ± 0.020.19 ± 0.035.6%0.970.34490.4798Cortex0.14 ± 0.010.14 ± 0.01−0.5%−0.230.81910.8885MD x 10^−3^ \[mm^2^/s\]Whole WM0.63 ± 0.020.66 ± 0.035.7%3.680.0017***0.0065***NAWM0.63[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}0.63 ± 0.02−0.2%−0.180.85660.8987DWM0.63[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}0.69 ± 0.059.8%3.990.0009***0.0036***WM lesions0.63[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}1.07 ± 0.1570.5%9.120.0000***0.0000***Thalamus0.65 ± 0.010.65 ± 0.020.7%0.700.49010.6273Amygdala0.71 ± 0.020.71 ± 0.02−0.1%−0.120.90850.9229Hippocampus0.75 ± 0.020.77 ± 0.022.5%2.160.04420.0991Basal ganglia0.64 ± 0.020.64 ± 0.020.1%0.080.93940.9394Cortex0.67 ± 0.010.67 ± 0.010.7%0.900.37830.5151AD x 10^−3^ \[mm^2^/s\]Whole WM1.042 ± 0.021.077 ± 0.023.4%4.070.0007N/ANAWM1.042[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}1.032 ± 0.02−1.0%−1.070.3005N/ADWM1.042[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}1.121 ± 0.057.6%5.010.0001N/AWM lesions1.042[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}1.513 ± 0.1945.2%7.660.0000N/AThalamus0.896 ± 0.010.912 ± 0.021.8%2.440.0255N/AAmygdala0.855 ± 0.030.864 ± 0.031.1%0.730.4720N/AHippocampus0.889 ± 0.030.903 ± 0.021.6%1.250.2274N/ABasal ganglia0.768 ± 0.030.776 ± 0.031.0%0.750.4646N/ACortex0.818 ± 0.020.823 ± 0.010.6%1.030.3151N/ARD x 10^−3^ \[mm^2^/s\]Whole WM0.439 ± 0.02[\*](#tb2fn1){ref-type="table-fn"}0.477 ± 0.038.7%3.210.0048N/ANAWM0.439[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}0.452 ± 0.023.0%1.360.1916N/ADWM0.439[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}0.528 ± 0.0620.3%4.650.0002N/AWM lesions0.439[\*](#tb2fn1){ref-type="table-fn"} ± 0.02[\*](#tb2fn1){ref-type="table-fn"}0.914 ± 0.15108.2%9.980.0000N/AThalamus0.531 ± 0.010.53 ± 0.03−0.2%−0.170.8662N/AAmygdala0.658 ± 0.020.652 ± 0.02−0.9%−0.720.4787N/AHippocampus0.71 ± 0.020.732 ± 0.023.1%2.590.0184N/ABasal ganglia0.588 ± 0.020.587 ± 0.02−0.2%−0.090.9291N/ACortex0.65 ± 0.010.656 ± 0.010.9%0.950.3530N/ADegree CentralityThalamus−0.264 ± 0.196−0.134 ± 0.120−49.3%1.790.09000.1600Amygdala−0.498 ± 0.173−0.533 ± 0.2697.1%−0.350.73190.8560Hippocampus−0.186 ± 0.215−0.213 ± 0.21014.1%−0.280.78600.8825Basal ganglia−0.329 ± 0.236−0.224 ± 0.138−32.1%1.220.23760.3620Cortex0.089 ± 0.0360.092 ± 0.0413.7%0.190.85180.8987Regional HomogeneityThalamus0.142 ± 0.0200.138 ± 0.021−2.8%−0.430.67510.8152Amygdala0.123 ± 0.0210.120 ± 0.017−2.4%−0.340.73710.8560Hippocampus0.134 ± 0.0170.127 ± 0.017−4.7%−0.830.41820.5463Basal ganglia0.153 ± 0.0150.151 ± 0.019−1.2%−0.240.80960.8885Cortex0.262 ± 0.0480.259 ± 0.047−0.96%−0.120.90720.9229[^1]

3.4. Comparison of rotating frame relaxation protocols with other modalities {#sec0011}
----------------------------------------------------------------------------

The T1ρ and T2ρ relaxation time constants ([Table 2](#tbl0002){ref-type="table"}) were in line with our previous reports ([@bib0034], [@bib0032]). All the rotating frame methods were able to detect differences between the healthy controls whole WM and MS patients whole WM. T1ρ and RAFF4 additionally detected differences between healthy controls whole WM and each of the 3 segmented WM ROIs (NAWM, DAWM, WM lesions) for MS patients ([Table 2](#tbl0002){ref-type="table"}). Specifically, there was a significant shift of the relaxograms in MS patients to longer relaxation times in T1ρ, T2ρ, and RAFF4 ([Fig. 3](#fig0003){ref-type="fig"}). In NAWM, there was a significant relaxation prolongation in both T1ρ and RAFF4 as compared to healthy controls' whole WM. Although T1w/T2w ratio and MD detected certain differences in the whole WM masks, these methods were unable to distinguish the two groups in the NAWM mask. DAWM mean relaxation times (T1ρ, T2ρ and RAFF4) in MS patients were once again significantly longer than in the WM of healthy controls. Mean differences in DAWM as compared to healthy control WM were also picked up by the T1w/T2w ratio, FA and MD. Lastly, all the MRI protocols relevant for WM confirmed significant changes between the respective parameters in WM lesions of MS patients and whole WM of healthy controls. For details, see [Table 2](#tbl0002){ref-type="table"}.Fig. 3Relaxograms of white matter (WM) MRI parameters RAFF4 (A), T1ρ (B), and T2ρ (C). Logarithmic *y*-axis scale (voxel count) and linear *x*-axis scale (relaxation parameter). Lines correspond to average values and shadows to ranges in the respective groups. Healthy controls depicted in green, MS patients in red. Furthermore, the group differences in average relaxogram (healthy controls minus MS patients) are shown (D), providing further information on the character of the observed relaxogram shift and maxima/minima of differences. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 3

Analogous analyses, which included also rsfMRI parameters, were performed for cortical GM and several subcortical regions. Only T1ρ, T2ρ and RAFF4 were able to reveal statistically significant results, namely prolonged relaxation time constants in hippocampus ([Table 2](#tbl0002){ref-type="table"}). No further cortical or subcortical GM differences were found between MS and controls. Interestingly, these microstructural changes were not reflected at the macrostructural level, as no significant differences in GM volume were found (see Supplementary Table 1).

3.5. Histogram and scatterplot analyses {#sec0012}
---------------------------------------

The relaxograms of whole WM for healthy subjects and MS patients exhibit a clear shift of the mode towards longer relaxation time constants in T1ρ and RAFF in MS patients ([Fig. 3](#fig0003){ref-type="fig"}). Additional histograms of DTI metrics and T1w/T2w ratio are presented in [Fig. 4](#fig0004){ref-type="fig"}. While there were substantial MS-related deformations of T1ρ and T2ρ relaxograms, as reflected visually and in significant differences in kurtosis and skewness (*p* \< 0.01 for both kurtosis and skewness in both T1ρ and T2ρ; see [Table 3](#tbl0003){ref-type="table"}), the shapes of RAFF relaxograms in MS patients and healthy controls exhibited substantial similarities (neither kurtosis, nor skewness between-group differences were found, *p* \> 0.20). Furthermore, the group difference relaxograms shown in [Fig. 3](#fig0003){ref-type="fig"} clearly confirm the shift of the above described relaxograms, with the peak differences in the relaxation time constants observed at about 70 ms, 130 ms, and 240 ms in T2ρ, T1ρ and RAFF4, respectively. Note that there is a trend of broader histograms also for MD and RD in MS patients ([Fig. 4](#fig0004){ref-type="fig"}), however kurtosis differences did not reach significance for either MD (see [Table 2](#tbl0002){ref-type="table"}) or RD (data not shown).Fig. 4Histograms of diffusion tensor imaging parameters \[fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD)\] and T1w/T2w ratio in white matter (WM). Logarithmic *y*-axis scale (voxel count), linear *x*-axis scale (individual parameters). Lines correspond to average values and shadows to ranges in the respective groups. Healthy controls depicted in green, MS patients in red. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 4Table 3Between-person averages of within-ROI histogram kurtosis and skewness for respective parameters in MS patients and healthy controls in whole white matter. *T*-test, false discovery rate corrected for multiple modalities (6) and histogram shape measures (2). Statistically significant results (*p* \< 0.05, corrected) are marked in bold italics. Positive *T*-values denote higher values of respective parameters in MS patients.Table 3Average KurtosisAverage SkewnessHealthy controlsMS patients*t*-value*p*Healthy controlsMS patients*t*-value*p*RAFF420.4419.79−0.6920.5944.214.14−0.7300.594T1ρ37.3230.74−3.915***0.003***5.805.21−4.137***0.003***T2ρ18.6613.77−4.475***0.002***4.023.40−4.593***0.002***T1w/T2w ratio130.66122.47−1.1130.42110.9310.40−1.7530.166FA2.062.080.3430.7350.730.750.6180.594MD23.2020.13−1.8490.1624.494.15−1.9660.156

The scatterplot analysis ([Fig. 5](#fig0005){ref-type="fig"}A) presents an appreciable clustering of the two subject groups, allowing us to estimate a T1ρ cut-off line of about 137 ms. [Fig. 5](#fig0005){ref-type="fig"}B shows a clear separation between the ROI-averaged values for NAWM, DAWM and lesional WM in MS patients. Finally, the correlation analysis of individual clinical parameters of interest with mean ROI values for relevant MRI metrics failed to provide any significant findings.Fig. 5Scatter plots, displaying mean T1ρ (*x*-axis) and mean T2ρ (y-axis) relaxation times of (A) white matter (WM) in healthy controls (green dots) and MS patients (red squares); and (B) normal appearing WM (NAWM) (blue diamonds), diffusely abnormal WM (yellow triangles) and lesions (red squares) in MS patients. Both (A) and (B) show significant clustering tendencies. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 5

4. Discussion {#sec0013}
=============

Building on our previous pilot study utilizing rotating frame relaxation parameters for the characterization of NAWM of MS ([@bib0032]), here we extended the imaging protocol to a clinically relevant platform (3 Tesla), to multi-slice acquisitions for extensive brain coverage, and to the inclusion of RAFF4, a measure exceptionally sensitive to myelin content ([@bib0051]). In general, the currently presented findings confirmed the ability of rotating frame methods to detect abnormalities of the NAWM and also GM structures, where well-established DTI metrics seem to fail. The calculation of the relaxograms for the various MRI metrics provided a robust characterization of the regions of interest which goes beyond what can be implicated by the mean values alone. This approach indeed enabled us to appreciate more delicate changes as skewness and kurtosis alterations in T1ρ and T2ρ WM relaxograms together with a shift to longer relaxation times, presumably reflecting a combination of diffuse WM changes and focal effects leading to the deformation of the right-side tail of the relaxogram. This notion is of major interest considering the ability of T1ρ to distinguish also general MS-related changes in NAWM, contrary to T2ρ. On the other hand, the simple shift of RAFF4 WM relaxogram to longer relaxation times without any shape deformation and its sensitivity to NAWM changes points to a rather unique ability of rotating frame protocols, when used in combination, to distinguish MS changes of diverse nature.

In the light of the previously demonstrated sensitivity of T1ρ to neuronal cellular density ([@bib0037], [@bib0036]) and T2ρ to iron levels ([@bib0040]; [@bib0037]), the interpretation of these alterations may not be as straightforward as in RAFF4, which strongly correlates with the myelin content ([@bib0051]). Interestingly, the ability of rotating frame relaxation protocols implemented in this study to detect different, although partly overlapping motional regimens, beyond the spectrum of imaging methods widely used in clinical practice, might be reflected in different and relevant aspects of WM changes. The prolongation of T2ρ relaxation in the whole WM, accentuated in DAWM, corroborate well with current theories of iron level dysregulation in MS and its depletion in WM, mainly in chronic lesions ([@bib0057]). Considering the crucial importance of iron levels for maintaining proper function of enzymatic systems essential for oligodendrocyte progenitor cells and hence remyelination, the ability to monitor its concentration might prove of paramount importance for newer generations of DMTs ([@bib0021]; [@bib0045]). Moreover, it is rather tempting to hypothesize that T1ρ relaxation prolongation in NAWM, a marker related to neuronal density as confirmed by histological studies in animals ([@bib0036]), should capture axonal degeneration, corroborated by the RAFF4 changes in both NAWM and whole WM ROIs. Furthermore, T1ρ, T2ρ and RAFF4 were able to identify significant differences from controls in hippocampus -- a deep grey matter structure of paramount importance for the clinical condition and well-being of each MS patient. These findings may yet prove to be of utmost relevance for the detection of early MS changes, as even rsfMRI measures, previously often hypothesized as early markers of impeding structural alterations in MS patients ([@bib0013]; [@bib0047]; [@bib0009]), failed to find any between-group differences in our study.

4.1. T1ρ focal abnormities {#sec0014}
--------------------------

Furthermore, the unique focal T1ρ abnormities which appeared as faster T1ρ relaxation and were undetectable by other MRI protocols, were observed in several MS patients, but not in healthy controls, and raise several intriguing questions. Not only the nature of pathology leading to these changes is of major interest, but also the implications of highly suspected lesions merit further research, as the current clinical MRI protocols and even several rotating frame relaxation methods such as RAFF4 and T2ρ are blind to them. In fact, the ability of a relaxation method to detect changes in tissue properties ultimately requires inherent sensitivity to the relevant relaxation channels while avoiding excessive shortening (or lengthening) of the relaxation time to avoid compromising accurate signal detection. As we have demonstrated previously, short T1ρ relaxation in tissue could arise from a pool of spins experiencing dipolar interactions with short correlation time, in the range of tens of nanoseconds or less, indicative of restricted mobility ([@bib0033]). Notably, the T2ρ of these spins with restricted mobility would be even shorter than T1ρ. If such spins are also in exchange with free-like moving spins at a different chemical shift (due for instance to the presence of iron) and since the dynamic range of T2ρ is greater than T1ρ, the resulting anisochronous exchange --induced relaxation would not significantly affect T1ρ, but would make T2ρ as well as T2 so short that could escape detection in T2ρ and T2 acquisitions. On the other hand, RAFF4 relaxation times generally become substantially shorter in presence of more restricted motions than those shortening adiabatic T1ρ ([@bib0022]), and they are not significantly impacted by fast exchange especially if the periodicity of RAFF4 irradiation is not tuned to the difference in chemical shifts of the two pools ([@bib0028]). These qualitative arguments demonstrate the importance for rotating frame relaxation techniques to be tuned to the relevant regimes of motion, and explain why some lesions may appear in T1ρ, but not in T2ρ, T2 or RAFF4 acquisitions. Nonetheless, all these parameters likely provide complementary information on NAWM/WM changes encompassing multiple factors, including factors relevant to disease pathology, and also perhaps associated with tissue characteristics not affected by MS. There were no differences in the clinical characteristics of MS patients with and without these focal T1ρ abnormities. However, as there were no comparable findings in any healthy controls and considering our previous studies showing T1ρ abnormalities in MS patients ([@bib0034]), these findings are intriguing in terms of T1ρ providing a novel non-invasive method for detecting CNS pathology in MS. Although an artefactual explanation for these "lesions" cannot be completely excluded, the size, shape and location of them are completely consistent with the well-established CNS pathology of MS. Further studies will be necessary to elucidate this issue fully.

4.2. Comparison of rotating frame relaxation protocols with other modalities {#sec0015}
----------------------------------------------------------------------------

Other modalities such as DTI ([@bib0053]), magnetization transfer ([@bib0048]), T1w/T2w ratio ([@bib0005]) or multi-exponential T2 ([@bib0035]) have the potential to assess tissue organization as well. However, the specificity of DTI measures to the underlying macroscopic-level organization of fibres was not a marker sufficient to provide results comparably significant to the approaches based on rotating frame relaxation in our study. FA and MD indeed failed to reach statistical significance in NAWM ROIs, while FA revealed relevant differences only in the areas previously marked as suspicious based on the T2-weighted intensities. Furthermore, even though T1w/T2w ratio in WM was previously reported in MS studies ([@bib0005]), it may not necessarily reflect the content or integrity of myelin ([@bib0061]), lacking histological studies except for cortical regions ([@bib0019]). It is nonetheless a parameter exhibiting plausible ability to detect WM changes in MS and as such definitely deservers further attention. All in all, the main objective of the presented study -- to show the superiority of the novel rotating frame MRI protocols to the commonly used metrics as DWI, T1w/T2w ratio for white matter and rsfMRI metrics for grey matter has been clearly met. Interestingly, rotating frame MRI protocols were the only ones able to detect any GM changes, surpassing functional MRI metrics, even though functional connectivity changes are often thought to precede MRI-detectable structural changes.

The promises of advanced quantitative MRI techniques have not been actualized in clinical practice yet, where T2-weighted and contrast-enhanced T1-weighted MRI scans remain the modalities of choice for monitoring clinically silent disease progression and detection of acute inflammation (Massimo [@bib0015]; [@bib0062]). These "traditional" approaches unfortunately fail to provide information possibly integral to MS clinical management like early detection of microstructural changes and more specific subclinical disease progression, with the ultimate goal to evaluate the response to advanced therapeutic regimens. Despite the promising results, one limitation of the current study is the absence of validation in a longitudinal manner and between individual MS centres. Because of the cross-sectional design, we are not able to provide further information on the stability of parameters in individual subjects over time, even though the narrow inter-subject range of values would suggest favourable prospects in this regard. Further study on the temporal evolution in a cohort larger than in the present study would likely shed light on this matter and would avoid problems inherently associated with higher number of metrics and statistical analyses in a smaller cohort of subjects as is the case in the currently presented study. In addition, integration of the current imaging protocols into general practice might be partially limited by the length of the acquisition protocol (about 20 min for all three rotating frame relaxation measurements) and the relatively low spatial resolution. On a positive note, both limitations may be solved using faster readout schemes and parallel acquisition protocols. Secondly, the semi-automatic approach implemented in the differentiation of NAWM, DAWM and lesions with fixed thresholds is associated with a risk of several artefact types (e.g. the inclusion of juxtacortical WM voxels into DAWM mask). However, these small problematic regions are not reflected in the relevant ROI analyses due to the lower resolution of rotating frame and DWI protocols and the conservative thresholding of coregistered ROI masks. All in all, this approach provided the most reasonable NAWM, DAWM and lesion masks as the thresholds of T2w intensities corresponding to DAWM and lesions were chosen by an experienced MS specialist. Finally, it is worth mentioning that motion artefacts did not appear to be a problem which may have compromised data quality, as confirmed by the very tight distribution of relaxation values in healthy controls. Despite the relatively low resolution implemented here, the rotating frame relaxations provided valuable information on WM characteristics, to the extent allowing for differentiation between healthy and MS subjects based on both T1ρ and T2ρ relaxation times with viable sensitivity and specificity of the chosen threshold; however, validation in a much larger cohort is warranted.

5. Conclusions {#sec0016}
==============

Taken together, the rotating frame relaxation techniques demonstrated the ability to detect abnormalities not only in WM and specifically NAWM, but also in deep grey matter, possibly describing a wide spectrum of different, albeit interconnected pathological features of MS, including the loss of neuronal cells and their axons, decreased levels of myelin even in NAWM, and reduced iron content. Ergo, these methods hold promise as potential non-invasive tools for monitoring MS activity and eventually for the evaluation of therapeutic effects, even though substantial efforts will need to be invested to ensure the implementation, harmonization and full interpretation of rotating frame relaxation protocols for clinical practice in MS.
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[^1]: since controls did not have MS pathology, the value used for the group comparison is the same as for the whole WM.
